Xvivo Perfusion AB (LTS:0RKL)
kr 471.13141 -2.4818 (-0.52%) Market Cap: 15.12 Bil Enterprise Value: 14.69 Bil PE Ratio: 73.15 PB Ratio: 7.28 GF Score: 89/100

Q4 2022 Xvivo Perfusion AB Earnings Call Transcript

Jan 26, 2023 / 01:00PM GMT
Release Date Price: kr209.06 (-3.54%)
Operator

Ladies and gentlemen, welcome to the XVIVO Report on Operations 2022. (Operator Instructions) I will now hand over to Christoffer Rosenblad, CEO. Please go ahead.

Christoffer Rosenblad;publ;CEO
Xvivo Perfusion AB

()-

Thank you so much, and welcome to you all to XVIVO's earnings call for the fourth quarter of 2022 and also on the Report on Operation for the full year 2022. With that, we go to the next slide. Today's presenter are myself, Christoffer Rosenblad, I'm CEO of XVIVO. And on the side, I have Kristoffer Nordstrom, CFO, who will give you a deep dive into the financials.

And with that, we start the actual presentation. On Slide 3, we find the financials for Q4 at the glance. And I'm both very proud and happy to report that Q4 was the strongest quarter we ever had posted by XVIVO. Sales reached SEK 132 million. And we have an organic growth of 27%, a total growth of 53%, where we had some good tailwind from currency effects as well as acquired growth. Very stable EBITDA on 15%. We can also see that we show good

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot